Work

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

Year: 2011

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Schizophrenia Research

DOI: 10.1016/j.schres.2011.11.001

Authors: Daniel C. Javitt, Robert W. Buchanan, Richard S.E. Keefe, Robert Kern, Robert P. McMahon, Michael F. Green, Jeffrey Lieberman, Donald C. Goff, John G. Csernansky, Joseph P. McEvoy, Fred Jarskog, Larry J. Seidman, James M. Gold, David Kimhy, Karen S. Nolan, Deanna S. Barch, M. Patricia Ball, James Robinson, Stephen R. Marder

Institutions: Nathan Kline Institute for Psychiatric Research, Duke Medical Center, University of California, Los Angeles, Columbia University Irving Medical Center, Harvard University, Massachusetts General Hospital, Washington University in St. Louis

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Public Health Service, National Institute of Mental Health

Awards: G280324529, G575830593

OpenAlex ID: W2169726711

FWCI: 8.077

Cites: 39

Cited by: 118

Related to: 10